These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2381619)

  • 21. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
    Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
    Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
    J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
    Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
    Ito K; Udagawa Y; Nozawa S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer.
    Carpelan-Holmström MA; Haglund CH; Järvinen HJ; Roberts PJ
    Anticancer Res; 1996; 16(2):981-6. PubMed ID: 8687164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
    Cirkel U; Ochs H; Latussek B; Schneider HP
    Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J; Qian H; Tian Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.